Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial

CONCLUSIONS: TILT-123 was safe and able to produce anti-tumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, NCT06125197).PMID:38546220 | DOI:10.1158/1078-0432.CCR-23-3874

Source: Clinical Cancer Research - March 28, 2024 Category: Cancer & Oncology Authors: Santeri A Pakola Katriina J Peltola James H A Clubb Elise Jirovec Lyna Haybout Tatiana V Kudling Tuomo Alanko Riitta Korpisaari Susanna Juteau Marjut Jaakkola Jorma Sormunen Jukka Kemppainen Annabrita Hemmes Teijo Pellinen Mirte van der Heijden Dafne C A Source Type: research